A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y 6J4
- University of Calgary, Peter Lougheed Centre
-
Edmonton, Alberta, Canada, T6G 2C8
- University of Alberta
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital/University of British Columbia
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- St. Boniface Hospital
-
-
Ontario
-
London, Ontario, Canada, N6A 4G5
- Victoria Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2L4M1
- Notre-Dame Hospital du CHUM
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis Medical Center, Division of Pulmonary and Critical Care Medicine
-
Stanford, California, United States, 94305
- Stanford University, Pulmonary & Critical Care Clinic
-
-
Florida
-
Miami, Florida, United States, 33101
- University of Miami Miller School of Medicine
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisenger Center for Clinical Studies
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Vermont
-
Colchester, Vermont, United States, 05446
- Vermont Lung Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females of non-childbearing potential ≥50 years of age (at the time of signing the informed consent document) with documented IPF
Diagnosis of IPF based on current ATS/ERS guidelines
- Usual interstitial pneumonia (UIP) pattern on HRCT and/or UIP pattern on histopathology (ie surgical lung biopsy), and
- Exclusion of known causes of interstitial lung disease (such as environmental exposure, connective tissue disease and drug toxicity), Or
- UIP pattern on surgical lung biopsy required if HRCT is inconsistent with UIP
Exclusion Criteria:
- FVC : < 50% predicted >90% predicted
- DLco:< 25% predicted >90% predicted
- Saturated oxygen (SpO2) of <92% (room air [sea level] at rest). SpO2 of < 88% (room air [≥ 5,000 feet above sea level (1524 meters]) at rest)
- Use of any cytotoxic/immunosuppressive agent (other than prednisone ≤ 12.5 mg/day or equivalent) including, but not limited to, azathioprine, cyclophosphamide, methotrexate and cyclosporine within 4 weeks of screening
Use of any cytokine modulators:
- Use of any biologic agent (such as etanercept, adalimumab, efalizumab, infliximab, golimumab, certolizumab) within 12 weeks or five half-lives of screening, and in the case of rituximab, use within 24 weeks of screening or no recovery of CD 19-positive B lymphocytes if the last dose of rituximab has been more than 24 weeks prior to screening
- Alefacept within 24 months of randomization
- Use of any therapy targeted to treat IPF (including but not limited to d-penicillamine, endothelium receptor antagonist [eg bosentan, ambrisentan], interferon gamma-1B, pirfenidone) within 4 weeks of screening
- Use of n-acetylcysteine (NAC) for IPF (≥1800 mg/day) within 4 weeks of screening
- Use of any investigational drug within one month of screening, or 5 PD/PK half lives, if known (whichever is longer)
- Current smoker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Placebo
|
|
EXPERIMENTAL: Cohort 1
• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
|
CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
|
|
EXPERIMENTAL: Cohort 2
• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
|
CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
|
|
EXPERIMENTAL: Cohort 3
• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
|
CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: Week 4
|
Number of participants with adverse events
|
Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long-term safety
Time Frame: Weeks 52-104
|
Number of participants with adverse events
|
Weeks 52-104
|
|
Disease progression/death rates
Time Frame: Up to week 56
|
Time to disease progression and death
|
Up to week 56
|
|
Disease progression/death rates
Time Frame: Weeks 52-104
|
Time to disease progression and death from week 52
|
Weeks 52-104
|
|
Pharmacokinetics-Cmax
Time Frame: Week 1 (baseline) and week 2
|
Maximum observed concentration in plasma
|
Week 1 (baseline) and week 2
|
|
Pharmacokinetics-Cmin
Time Frame: Week 0 (baseline) and week 2
|
Minimum observed concentration in plasma
|
Week 0 (baseline) and week 2
|
|
Pharmacokinetics-AUC
Time Frame: Week 0 (baseline) and week 2
|
Area under the plasma concentration - time curve
|
Week 0 (baseline) and week 2
|
|
Pharmacokinetics-Tmax
Time Frame: Week 0 (baseline) and week 2
|
Time to reach Cmax
|
Week 0 (baseline) and week 2
|
|
Pharmacokinetics - t 1/2
Time Frame: Week 0 (baseline) and week 2
|
Terminal half-life (t1/2)
|
Week 0 (baseline) and week 2
|
|
Pharmacokinetics-Vz/f
Time Frame: Week 0 (baseline) and week 2
|
Apparent volume of distribution
|
Week 0 (baseline) and week 2
|
|
Pharmacokinetics-CL/F
Time Frame: Week 0 (baseline) and week 2
|
Apparent total body clearance
|
Week 0 (baseline) and week 2
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CC-930-IPF-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.